Efficacy and safety assessment of apatinib in patients with advanced gastric cancer: a meta-analysis

Figures & data

Table 1 The characteristics of included studies

References	Status of treatment	Treatment arms	Cases	End points
Li et al^Citation6	Second-line or further	Apatinib Placebo	181 92	ORR/DCR/PFS/OS
Li et al^Citation10	Second-line or further	Placebo Apatinib 850 mg Qd* Apatinib 425 mg Bid**	48 48 48	ORR/DCR/PFS/OS
Zhu et al^Citation11	Second-line or further	PTX or 5-FU or CPT-11 Above+apatinib	39 32	ORR/DCR
Gao et al^Citation12	Second-line or further	Apatinib+S-1 S-1	16 15	ORR/DCR
Gao and Fang^Citation13	First-line	Apatinib+FOLFIRI FOLFIRI***	40 40	ORR/DCR
Wen et al^Citation14	First-line	Apatinib+SOX SOX****	45 45	ORR/DCR
Chen et al^Citation15	Second-line or further	Apatinib S-1	50 49	ORR
Ding et al^Citation16	Second-line or further	Apatinib S-1	30 30	ORR/DCR
Lang et al^Citation17	Second-line or further	Apatinib Placebo	14 14	ORR/DCR
Fan et al^Citation18	First-line	Apatinib+S-1 S-1	15 15	ORR/DCR
Wang et al^Citation19	First-line	Apatinib+PS PS*****	29 29	ORR
Wang et al^Citation20	Second-line or further	Apatinib S-1	25 25	ORR
Xue and Cui^Citation21	Second-line or further	Apatinib Placebo	25 30	ORR

Notes:

* Qd: one time a day.

** Bid: two times a day.

*** FOLFIRI: irinotecan+fluorouracil+leucovorin.

**** SOX: oxaliplatin+S-1.

***** PS: nedaplatin+S-1.

Abbreviations: 5-FU, 5-fluorouracil; CPT-11, irinotecan; DCR, disease control rate; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PTX, paclitaxel; S-1, tegafur gimeracil oteracil potassium capsule.

Figure 1 Study selection procedure with PRISMA flow diagram.

Abbreviations: PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCTs, randomized controlled trials.

Figure 2 Forest plot of ORR (A) and DCR (B) between apatinib-alone or apatinib-based regimens and no-apatinib groups.

Abbreviations: CI, confidence interval; DCR, disease control rate; M–H, Mantel–Haenzel; ORR, objective response rate.

Figure 3 Forest plot of hematological toxicity (A), digestive events (B), and general events (C1 and C2) between apatinib-alone or apatinib-based regimens and no-apatinib groups.

Abbreviations: CI, confidence interval; M–H, Mantel–Haenzel.

Figure 4 Funnel plot for publication bias with ORR.

Abbreviations: OR, odds ratio; ORR, objective response rate; SE, standard error.

LiJQinSXuJRandomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroe-sophageal junctionJ Clin Oncol201634131448145426884585

 PubMed Web of Science ®Google Scholar

LiJQinSXuJApatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trialJ Clin Oncol201331263219322523918952

 PubMed Web of Science ®Google Scholar

ZhuHSunXZhouQChenLChenJWuPClinical study of Apatinib combined chemotherapy in the treatment of advanced gastric cancerChin J Surg Oncol201686394396

 Google Scholar

GaoJHanTPiaoYApatinib combined tegafur in treatment for elderly or emaciated patients with advanced gastric cancerClin J Med Offic2017451912

 Google Scholar

GaoFFangXThe short term efficacy of apatinib combined with CPT-11 and 5-FU in patients with advanced gastric cancerClin Album2016126624625

 Google Scholar

WenFXiangYWangLClinical trial of apatinib tablets in the treatment of advanced gastric cancerClin Study2017337589591

 Google Scholar

ChenZZhengQGuoBComparison of apatinib and S-1 in second line treatment of advanced gastric cancerChin J Clin Ratl Drug Use2017106A7980

 Google Scholar

DingLXiaYWangWMengMYaoRBiJEfficacy and prognosis assessment of apatinib and S-1 in patients with advanced gastric cancerJ Anhui Tech Coll Health20171624849

 Google Scholar

LangFZhaoYFanPClinical efficacy and safety of apatinib mesylatefor patients with advanced gastric cancerPract J Cancer2017326996998

 Google Scholar

FanXLvHChenBClinical study of Apatinib combined with S-1 in the treatment of patients with advanced gastric cancer and review of literatureChin J Med Front2017926367

 Google Scholar

WangDSongSWangKEfficacy assessment of apatinib combined with chemotherapy in patients with advanced gastric cancerWorld Latest Med Inf20161687130131

 Google Scholar

WangPShangNLiuZDongXClinical research of apatinib combined with S-1 in patients with advanced gastric cancerJ Taishan Med Coll2016378919920

 Google Scholar

XueDCuiLEfficacy assessment of apatinib in the treatment after failure of second line chemotherapy in patients with advanced gastric cancerContemp Med Symp20161422126127

 Google Scholar